Hot Stocks
|
Vertex Pharmaceuticals… Vertex Pharmaceuticals announced the U.S. Food and Drug Administration, FDA, has granted inaxaplin, VX-147, Breakthrough Therapy Designation, BTD, for APOL1-mediated focal segmental glomerulosclerosis and the European Medicines Agency, EMA, has granted inaxaplin Priority Medicines, PRIME, designation for APOL1-mediated chronic kidney disease. Inaxaplin is the first investigational therapy aimed at treating the underlying cause of AMKD. Vertex now holds three of the approximately 70 non-oncological PRIME designations granted to date, including its two PRIME designations for exagamglogene autotemcel, formerly known as CTX001, one for transfusion-dependent beta thalassemia and one for sickle cell disease. In the US, this is the ninth breakthrough therapy designation granted to Vertex across its portfolio programs. ShowHide Related Items >><< VRTX Vertex Pharmaceuticals - 06/06/22
- Vertex Pharmaceuticals presents data from VX-880 Phase 1/2 clinical trial
- 06/02/22
- Vertex, Crispr Therapeutics say late-breaking CTX001 abstract accepted for EHA
- 05/23/22
- Catalyst Biosciences sells complement portfolio for $60M
- 05/18/22
- Vertex Pharmaceuticals appoints Suketu Upadhyay to board of directors
VRTX Vertex Pharmaceuticals - 06/01/22 Maxim
- Maxim upgrades Vertex Pharmaceuticals to Buy as company expands beyond CF
- 06/01/22 Maxim
- Vertex Pharmaceuticals upgraded to Buy from Hold at Maxim
- 05/23/22 Piper Sandler
- Piper Sandler remains bullish on Catalyst after sale of complement portfolio
- 05/23/22 SVB Leerink
- Vertex Pharmaceuticals initiated with a Market Perform at SVB Leerink
VRTX Vertex Pharmaceuticals - 05/05/22
- Vertex Pharmaceuticals reports Q1 adjusted EPS $3.52, consensus $3.49
- 05/05/22
- Notable companies reporting after market close
- 01/26/22
- Vertex Pharmaceuticals reports Q4 EPS $3.37, consensus $3.29
- 01/26/22
- Notable companies reporting after market close
VRTX Vertex Pharmaceuticals - 01/08/22
- Biotech due to bounce back, Vertex stands out, Barron's says
VRTX Vertex Pharmaceuticals - 06/01/22
- What You Missed On Wall Street On Wednesday
- 06/01/22
- What You Missed On Wall Street This Morning
- 06/01/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 05/23/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
VRTX Vertex Pharmaceuticals - 01/10/22
- Early notable gainers among liquid option names on January 10th
|
Hot Stocks
|
Vertex Pharmaceuticals… Vertex Pharmaceuticals provided additional data on patients dosed in Part A of its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with T1D with impaired hypoglycemic awareness and severe hypoglycemia. As reported last month, both patients treated with half the target dose of VX-880 achieved glucose-responsive insulin production, improvements in glycemic control and reductions in exogenous insulin requirements. The data presented today show significant increases in the blood glucose time-in-range compared to baseline, following treatment with VX-880. Time spent in target range is a clinically important metric in diabetes management that reflects the amount of time a patient's blood glucose level is measured in the desired, target blood sugar range. The accepted American Diabetes Association/European Association for the Study of Diabetes target for time-in-range is 70%. These data were presented during the American Diabetes Association 82nd Scientific Sessions Conference on June 6, 2022 in New Orleans, Louisiana from 9:00 to 9:15 a.m. CDT as an oral abstract presentation, "Stem Cell-Derived, Fully Differentiated Islet Cells for Type 1 Diabetes". The presentation included data from both patients dosed in Part A of the study, designed to assess the safety profile of VX-880 at half the target dose. Patient 1 showed a blood glucose time-in-range increase from 40.1% at baseline to 99.9% at Day 270 and was insulin independent. Patient 2 showed a time-in-range increase from 35.9% at baseline to 51.9% at Day 150 with a 30% reduction in exogenous insulin use. VX-880 has been generally well tolerated in all patients dosed to date, with the majority of adverse events being mild or moderate. Additional Vertex presentations at ADA this year included an oral presentation, "Persistence of Impaired Awareness of Hypoglycemia, Severe Hypoglycemic Events and Suboptimal Glycemic Control Despite Advanced Diabetes Technologies", and poster, "Gaps Remain in Achieving Target T1D Glycemic Goals Despite Advanced Technologies". To date, three patients have been dosed in the Phase 1/2 study with VX-880. Two patients received half the target dose of cells in Part A of the study. A third patient has received the full target dose in Part B of the study. Vertex is also pursuing additional programs in T1D, including one in which these same stem cell-derived islets are encapsulated in an immunoprotective device to be surgically implanted without the use of concomitant immunosuppression, and another program where cells are modified to produce hypoimmune stem cell-derived islets. IND-enabling studies for the encapsulated cells program are underway, and the company remains on track to submit an IND in 2022. ShowHide Related Items >><< VRTX Vertex Pharmaceuticals - 06/02/22
- Vertex, Crispr Therapeutics say late-breaking CTX001 abstract accepted for EHA
- 05/23/22
- Catalyst Biosciences sells complement portfolio for $60M
- 05/18/22
- Vertex Pharmaceuticals appoints Suketu Upadhyay to board of directors
- 05/17/22
- Vertex Pharmaceuticals announces expansion plans in Boston's Seaport
VRTX Vertex Pharmaceuticals - 06/01/22 Maxim
- Maxim upgrades Vertex Pharmaceuticals to Buy as company expands beyond CF
- 06/01/22 Maxim
- Vertex Pharmaceuticals upgraded to Buy from Hold at Maxim
- 05/23/22 Piper Sandler
- Piper Sandler remains bullish on Catalyst after sale of complement portfolio
- 05/23/22 SVB Leerink
- Vertex Pharmaceuticals initiated with a Market Perform at SVB Leerink
VRTX Vertex Pharmaceuticals - 05/05/22
- Vertex Pharmaceuticals reports Q1 adjusted EPS $3.52, consensus $3.49
- 05/05/22
- Notable companies reporting after market close
- 01/26/22
- Vertex Pharmaceuticals reports Q4 EPS $3.37, consensus $3.29
- 01/26/22
- Notable companies reporting after market close
VRTX Vertex Pharmaceuticals - 01/08/22
- Biotech due to bounce back, Vertex stands out, Barron's says
VRTX Vertex Pharmaceuticals - 06/01/22
- What You Missed On Wall Street On Wednesday
- 06/01/22
- What You Missed On Wall Street This Morning
- 06/01/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 05/23/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
VRTX Vertex Pharmaceuticals - 01/10/22
- Early notable gainers among liquid option names on January 10th
|
Hot Stocks
|
Vertex Pharmaceuticals… Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) announced new late-breaking clinical data accepted for oral presentation at the 2022 European Hematology Association, or EHA, Congress. Late-breaking abstract #LB2367 entitled "Efficacy and Safety of A Single Dose of CTX001 For Transfusion-Dependent undefinedeta-Thalassemia and Severe Sickle Cell Disease," will be an oral presentation on Sunday, June 12. The abstract from Vertex and CRISPR Therapeutics includes data on patients treated in CLIMB-111 and CLIMB-121 and followed in CLIMB-131 with CTX001, now known as exagamglogene autotemcel, or exa-cel. This abstract has been selected for the media briefing program and is therefore embargoed until Saturday, June 11. Vertex also announced three abstracts accepted for poster presentation at EHA. ShowHide Related Items >><< VRTX Vertex Pharmaceuticals - 05/23/22
- Catalyst Biosciences sells complement portfolio for $60M
- 05/18/22
- Vertex Pharmaceuticals appoints Suketu Upadhyay to board of directors
- 05/17/22
- Vertex Pharmaceuticals announces expansion plans in Boston's Seaport
- 05/05/22
- Vertex Pharmaceuticals still sees FY22 product revenues $8.4B-$8.6B
- 05/16/22
- Crispr Therapeutics appoints Morrow as CMO
- 05/13/22
- Crispr to present new clinical data on Anti-CD70 CAR-T Therapy for CTX130 at EHA
- 04/08/22
- Nkarta announces new preclinical data at AACR
- 02/02/22
- Crispr, ViaCyte announce first patient dosed in Phase 1 trial of VCTX210
VRTX Vertex Pharmaceuticals - 06/01/22 Maxim
- Maxim upgrades Vertex Pharmaceuticals to Buy as company expands beyond CF
- 06/01/22 Maxim
- Vertex Pharmaceuticals upgraded to Buy from Hold at Maxim
- 05/23/22 Piper Sandler
- Piper Sandler remains bullish on Catalyst after sale of complement portfolio
- 05/23/22 SVB Leerink
- Vertex Pharmaceuticals initiated with a Market Perform at SVB Leerink
- 05/23/22 Piper Sandler
- Crispr Therapeutics price target lowered to $115 from $180 at Piper Sandler
- 05/17/22 Citi
- Crispr Therapeutics price target lowered to $53 from $64 at Citi
- 05/13/22 Needham
- Crispr Therapeutics price target lowered to $122 from $170 at Needham
- 05/11/22 Oppenheimer
- Crispr Therapeutics price target lowered to $150 from $172 at Oppenheimer
VRTX Vertex Pharmaceuticals - 05/05/22
- Vertex Pharmaceuticals reports Q1 adjusted EPS $3.52, consensus $3.49
- 05/05/22
- Notable companies reporting after market close
- 01/26/22
- Vertex Pharmaceuticals reports Q4 EPS $3.37, consensus $3.29
- 01/26/22
- Notable companies reporting after market close
- 05/09/22
- Crispr Therapeutics reports Q1 EPS ($2.32), consensus ($1.94)
- 02/15/22
- Crispr Therapeutics reports Q4 EPS ($1.84), consensus ($1.77)
VRTX Vertex Pharmaceuticals - 01/08/22
- Biotech due to bounce back, Vertex stands out, Barron's says
VRTX Vertex Pharmaceuticals - 06/01/22
- What You Missed On Wall Street On Wednesday
- 06/01/22
- What You Missed On Wall Street This Morning
- 06/01/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 05/23/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
VRTX Vertex Pharmaceuticals - 01/10/22
- Early notable gainers among liquid option names on January 10th
- 05/20/22
- Largest borrow rate increases among liquid names
- 04/26/22
- Crispr Therapeutics options imply 5.6% move in share price post-earnings
- 01/10/22
- Crispr Therapeutics call volume above normal and directionally bullish
|
On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< - 06/01/22
- Victoria's Secret rises 8.9%
- 05/26/22
- Victoria's Secret launches VS&Co-Lab digital platform
- 04/29/22
- Victoria's Secret & PINK Beauty launch in Amazon's store
VRTX Vertex Pharmaceuticals - 05/23/22
- Catalyst Biosciences sells complement portfolio for $60M
- 05/18/22
- Vertex Pharmaceuticals appoints Suketu Upadhyay to board of directors
- 05/17/22
- Vertex Pharmaceuticals announces expansion plans in Boston's Seaport
- 05/05/22
- Vertex Pharmaceuticals still sees FY22 product revenues $8.4B-$8.6B
- 05/27/22
- Twitter board does not accept resignation of Silver Lake's Egon Durban
- 05/25/22
- Twitter up 9% after Elon Musk files amended 13D related to takeover agreement
- 05/25/22
- Musk commits to provide additional $6.25B in equity financing for Twitter deal
- 05/20/22
- Elon Musk: We will never surrender/settle an unjust case against us
- $740.48 /
-17.53 (-2.31%) - 05/30/22
- Fly Intel: Top five weekend stock stories
- 05/30/22
- Musk says Bill Gates has 'multi-billion dollar' Tesla short position
- 05/24/22
- Cathie Wood's ARK Investment bought 26.1K shares of Tesla today
- 05/23/22
- Cathie Wood's ARK Investment bought 15.9K shares of Tesla today
- 02/22/22
- Tempur Sealy falls -16.5%
- 02/22/22
- Tempur Sealy falls -13.0%
- 02/22/22
- Tempur Sealy falls -12.9%
- 02/22/22
- Tempur Sealy increases quarterly dividend to 10c per share
- 05/25/22
- Cathie Wood's ARK Investment bought 24.4K shares of Block today
- 05/24/22
- Cathie Wood's ARK Investment bought 222.3K shares of Block today
- 05/18/22
- Square acquires GoParrot digital ordering and marketing platform for restaurants
- 05/17/22
- Square expands Afterpay integration to in-person points of sale
- $332.10 /
-17.85 (-5.10%) - 06/01/22
- Morningstar completes acquisition of Leveraged Commentary & Data
- 06/01/22
- S&P Global falls -9.3%
- 04/13/22
- S&P Global names Daniel Yergin vice chairman
- 04/04/22
- S&P Global to sell LCD business to Morningstar for $650M in cash
- 06/01/22
- RedBall Acquisition, SeatGeek agree to terminate combination agreement
- 06/01/22
- RedBall Acquisition, SeatGeek agree to terminate combination agreement
OPA Magnum Opus Acquisition - 06/01/22
- Forbes Global Media ends SPAC deal with Magnum Opus Acquisition
- 04/11/22
- Forbes unveils preview of virtual Billionaires NFT collection
- 02/10/22
- Forbes and SPAC Magnum Opus announce Binance pact for Forbes to be listed
- 06/01/22
- NIO delivers 7,024 vehicles in May
- 05/20/22
- Nio up 7% in pre-market after company announced Singapore exchange listing
- 05/05/22
- Nio provides update on HFCAA status
- 05/01/22
- Nio delivers 5,074 vehicles in April 2022
- 06/01/22
- Zuckerberg says Javier Olivan to succeed Sandberg as Meta COO
- 06/01/22
- Sheryl Sandberg leaving Meta Platforms
- 05/31/22
- Meta Platforms to change ticker symbol to 'META' on June 9
- 05/20/22
- WhatsApp announces new products for business messaging
- 05/26/22
- Medtronic: Q1 EPS guidance includes FX headwind of about 5c
- 05/26/22
- Medtronic: Procedure volumes in most markets reached pre-Covid levels by Q4E
- 05/26/22
- Medtronic sees 'strong' improvement in 2H23, pipeline 'robust'
- 05/26/22
- Medtronic: Parts of quarter played out as anticipated, but unexpected challenges
- 06/01/22
- Levi Strauss trading resumes
- 06/01/22
- Levi Strauss approves $750M share repurchase authorization
- 06/01/22
- Levi Strauss trading halted, news pending
- 04/06/22
- Levi Strauss CFO says started 2022 very strong in terms of gross margin
- 05/13/22
- Starboard takes stake in Humana, exits System1
- 05/03/22
- Kala announces new commercial, Medicare coverage for EYSUVIS
- 04/21/22
- Humana to divest interest in Hospice, Personal Care divisions of KAH Hospice
- 02/22/22
- Humana to add two new independent directors in Starboard cooperation agreement
- 05/31/22
- HP Inc. CEO: Supply chain situation continues to be challenging
- 05/27/22
- Poly not providing FY23 guidance
- 05/23/22
- HP Inc. names Ernest Nicolas as chief supply chain officer
- 05/19/22
- HP Inc. debuts new HP Spectre, HP Envy laptops
- 05/17/22
- GoodRx announces strategic relationship with RxVantage
- 05/09/22
- GoodRx 'unlikely' to achieve guidance provided on Q4 earnings call
- 05/09/22
- GoodRx names former Uber grocery, new verticals chief Raj Beri as COO
- 05/02/22
- GoodRx partners with AssistRx
- $188.59 /
-4.965 (-2.57%) - 06/01/22
- Meta Platforms down 3% after COO Sandberg announces plan to leave
ENOB Enochian Biosciences - 05/25/22
- Enochian Biosciences says Gumrukcu 'has had no formal role in the company'
- 05/25/22
- Enochian BioSciences falls after Gumrukcu charged in murder-for-hire conspiracy
- 05/25/22
- Enochian Biosciences trading resumes
- 05/25/22
- Enochian Biosciences trading halted, volatility trading pause
- 06/01/22
- Delta jumps 2.5% in premarket trading after providing updated Q2 guidance
- 06/01/22
- Delta sees June quarter total unit revenues 7-8 pts better than expected
- 06/01/22
- Delta Air Lines sees June quarter revenue 'fully restored' to 2019
- 04/19/22
- DOJ to appeal ruling that lifted COVID mask mandate on travel
- $176.04 /
+15.44 (+9.61%) - 06/01/22
- Salesforce rises 10.3%
- 06/01/22
- Salesforce rises 13.3%
- 06/01/22
- Salesforce rises 11.6%
- 05/31/22
- Salesforce co-CEO Benioff: It was a remarkably healthy quarter
- 06/01/22
- Capri Holdings jumps 8% to $52.80 after Q4 results, FY23 guidance top estimates
- 06/01/22
- Capri Holdings announces new $1B share repurchase program
- 05/16/22
- David Einhorn's Greenlight adds Southwestern, exits Sonos in Q1
- 03/21/22
- Capri Holdings appoints Emmanuel Gintzburger CEO of Versace
- 06/01/22
- CareMax to acquire Medicare value-based care business of Steward Health Care
- 02/07/22
- CareMax names Jose Rodriguez as Chair of board of directors
- 05/02/22
- Roivant Sciences announces collaborations in targeted protein degradation
- 04/08/22
- Blueprint Medicines says SYMPHONY results support development expansion
- 03/25/22
- Blueprint Medicines' AYVAKYT receives EC approval for expanded indication
- 02/28/22
- Blueprint Medicines, Proteovant Therapeutics announces strategic collaboration
- 05/31/22
- Digital Turbine delays 10-K filing
- 05/17/22
- Digital Turbine says FY22 quarterly results to be restated
- 04/27/22
- Digital Turbine enters multiyear partnership with AccuWeather
- 02/16/22
- Google announces 'Privacy Sandbox on Android'
- 04/05/22
- Lumentum, Ambarella announce a new joint reference design Vision-D
- 03/28/22
- Ambarella hires new CFO, Brian White, formerly with Maxim Integrated Products
- 03/21/22
- Ambarella announces passing of CFO Casey Eichler
- 03/16/22
- Ambarella, Helm.ai announce ADAS software integration
- 05/24/22
- WooCommerce and Affirm expand partnership with Canada launch
- 05/12/22
- Affirm CEO: Our underlying business is performing very well
- 05/12/22
- Affirm jumps 22% to $21.97 after Q3 results beat, FY22 guidance raised
- 05/12/22
- Affirm extends multi-year partnership with Shopify in U.S.
- $150.02 /
-4.775 (-3.08%) - 06/01/22
- AmerisourceBergen says will introduce FY23 guidance in November
- 06/01/22
- AmerisourceBergen sinks 4% to $148.18 as investor day continues
- 06/01/22
- AmerisourceBergen announces new $1B share repurchase program
- 05/12/22
- AmerisourceBergen to resume share repurchases
- 05/25/22
- Luminar hires CJ Moore from Apple, Taner Ozcelik for technical team
- 05/25/22
- Luminar up 4% to $8.80 after Bloomberg report of Apple hire
- 05/16/22
- Berkshire Hathaway adds Citi, exits Wells Fargo in Q1
- 05/16/22
- Soros Capital buys Suncor and Mosaic during Q1, exits Alphabet
- $332.10 /
-17.85 (-5.10%) - 06/02/22 Deutsche Bank
- S&P Global price target lowered to $418 from $483 at Deutsche Bank
- 06/02/22 BMO Capital
- Moody's price target lowered to $309 from $331 at BMO Capital
- 06/02/22 BMO Capital
- S&P Global price target lowered to $365 from $433 at BMO Capital
- 06/02/22 Morgan Stanley
- Moody's price target lowered to $305 from $318 at Morgan Stanley
- $176.04 /
+15.44 (+9.61%) - 06/02/22 Loop Capital
- Salesforce price target lowered to $175 from $225 at Loop Capital
- 06/01/22 RBC Capital
- Salesforce margin outlook overshadowed lower revenue guide, says RBC Capital
- 06/01/22 BMO Capital
- Salesforce price target lowered to $225 from $260 at BMO Capital
- 06/01/22 Stifel
- Salesforce price target lowered to $250 from $300 at Stifel
- 06/01/22 Morgan Stanley
- Morgan Stanley stays Underweight on HP Inc. after Q2 report
- 06/01/22 Citi
- HP Inc. price target raised to $40 from $38 at Citi
- 06/01/22 Barclays
- HP Inc. price target raised to $32 from $29 at Barclays
- 05/25/22 JPMorgan
- HP Inc. price target lowered to $39 from $41 at JPMorgan
- 06/01/22 Goldman Sachs
- Delta Air Lines price target raised to $45 from $44 at Goldman Sachs
- 04/26/22 Northland
- SpaceX's Starlink deal with Hawaiian highlights risk for Gogo, says Northland
- 04/22/22 Morgan Stanley
- United Airlines price target raised to $67 from $62 at Morgan Stanley
- 04/22/22 JPMorgan
- Delta Air Lines price target raised to $70 from $69 at JPMorgan
OPA Magnum Opus Acquisition - 03/01/22 Benchmark
- Magnum Opus Acquisition initiated with a Buy at Benchmark
- 12/15/21 Cantor Fitzgerald
- Magnum Opus Acquisition price target raised to $14.50 from $10.00 at Cantor Fitzgerald
- 10/21/21 Cantor Fitzgerald
- Magnum Opus Acquisition initiated with an Overweight at Cantor Fitzgerald
- 06/01/22 Piper Sandler
- Tempur Sealy downgraded to Neutral from Overweight at Piper Sandler
- 04/12/22 Loop Capital
- Tempur Sealy price target lowered to $28 from $35 at Loop Capital
- 04/06/22 Raymond James
- Tempur Sealy price target lowered to $38 from $45 at Raymond James
- 04/01/22 Piper Sandler
- Tempur Sealy price target lowered to $34 from $40 at Piper Sandler
VRTX Vertex Pharmaceuticals - 06/01/22 Maxim
- Maxim upgrades Vertex Pharmaceuticals to Buy as company expands beyond CF
- 06/01/22 Maxim
- Vertex Pharmaceuticals upgraded to Buy from Hold at Maxim
- 05/23/22 Piper Sandler
- Piper Sandler remains bullish on Catalyst after sale of complement portfolio
- 05/23/22 SVB Leerink
- Vertex Pharmaceuticals initiated with a Market Perform at SVB Leerink
- 06/01/22 Jefferies
- Blueprint Medicines raised to Buy at Jefferies after survey on Ayvakit in ISM
- 06/01/22 Jefferies
- Blueprint Medicines upgraded to Buy from Hold at Jefferies
- 05/18/22 Piper Sandler
- Blueprint Medicines price target lowered to $65 from $84 at Piper Sandler
- 05/04/22 Baird
- Blueprint Medicines price target lowered to $96 from $123 at Baird
- 06/01/22 Baird
- Baird downgrades GoodRx to Neutral amid disruption at Kroger
- 06/01/22 Baird
- GoodRx downgraded to Neutral from Outperform at Baird
- 05/16/22 Baird
- Baird 'hypothesizing' GoodRx PBM/pharmacy issue at Kroger may be improving
- 05/12/22 Wells Fargo
- GoodRx price target lowered to $9 from $20 at Wells Fargo
- 06/01/22 Atlantic Equities
- Medtronic downgraded to Neutral from Overweight at Atlantic Equities
- 05/31/22 Raymond James
- Medtronic price target lowered to $109 from $116 at Raymond James
- 05/31/22 Truist
- Medtronic price target lowered to $111 from $121 at Truist
- 05/27/22 RBC Capital
- Medtronic price target lowered to $122 from $135 at RBC Capital
- 06/01/22 Macquarie
- Digital Turbine price target lowered to $40 from $70 at Macquarie
- 05/27/22 JPMorgan
- iPhone China shipments in April below seasonal, says JPMorgan
- 05/25/22 Loop Capital
- Loop Capital sees consensus for Apple's iPhone revenue in second half as low
- 05/24/22 BofA
- Apple App Store growth has re-accelerated modestly, says BofA
ENOB Enochian Biosciences - 05/23/22 Mizuho
- April delinquency trends promising for Affirm, says Mizuho
- 05/17/22 Mizuho
- Affirm price target lowered to $50 from $79 at Mizuho
- 05/16/22 Barclays
- Affirm price target lowered to $35 from $65 at Barclays
- 05/13/22 RBC Capital
- Affirm price target lowered to $48 from $58 at RBC Capital
- 06/01/22 Piper Sandler
- App downloads for Block's Cash App strong, says Piper Sandler
- 05/24/22 Morgan Stanley
- Morgan Stanley upgrades Marqeta to Overweight on attractive entry point
- 05/23/22 Truist
- Block price target lowered to $145 from $165 at Truist
- 05/23/22 Deutsche Bank
- Block price target lowered to $155 from $180 at Deutsche Bank
- $740.48 /
-17.53 (-2.31%) - 06/01/22 Goldman Sachs
- Tesla price target lowered to $1,000 from $1,200 at Goldman Sachs
- 05/31/22 Mizuho
- Tesla shutdown in Shanghai a near-term headwind, says Mizuho
- 05/27/22 Credit Suisse
- Tesla pullback brings attractive entry point, says Credit Suisse
- 05/26/22 Jefferies
- Jefferies cuts Tesla price target on governance risk, challenging market
- 06/02/22 Piper Sandler
- Twitter price target raised to $54.,20 from $51.50 at Piper Sandler
- 05/24/22 Jefferies
- Twitter price target lowered to $40 from $48 at Jefferies
- 05/24/22 Wedbush
- More fireworks expected heading into Twitter shareholder meeting, says Wedbush
- 05/24/22 KeyBanc
- Snap price target lowered to $27 from $45 at KeyBanc
- 05/10/22 BMO Capital
- Yelp price target lowered to $37 from $42 at BMO Capital
- 04/06/22 DA Davidson
- System1 price target raised to $26 from $23 at DA Davidson
- 03/25/22 UBS
- Meta Platforms newsfeed changes and Reelz to drive higher monetization, says UBS
- $188.59 /
-4.965 (-2.57%) - 06/02/22 Mizuho
- Meta Platforms' Sheryl Sandberg difficult to replace, says Mizuho
- 06/02/22 Piper Sandler
- Meta Platforms price target lowered to $220 from $230 at Piper Sandler
- 06/01/22 Morgan Stanley
- Meta Platforms price target lowered to $300 from $330 at Morgan Stanley
- 06/01/22 Morgan Stanley
- Meta Platforms price target lowered to $300 from $330 at Morgan Stanley
- 06/02/22 Credit Suisse
- Capri Holdings price target lowered to $65 from $74 at Credit Suisse
- 06/02/22 Baird
- Capri Holdings price target lowered to $75 from $85 at Baird
- 04/19/22 OTR Global
- Tapestry view downgraded to Mixed from Positive at OTR Global
- 04/19/22 Barclays
- Capri Holdings price target raised to $74 from $72 at Barclays
- 06/02/22 Barclays
- Victoria's Secret price target lowered to $60 from $61 at Barclays
- 06/01/22 JPMorgan
- Victoria's Secret price target lowered to $57 from $71 at JPMorgan
- 06/01/22 Wells Fargo
- Victoria's Secret price target lowered to $60 from $70 at Wells Fargo
- 05/16/22 JPMorgan
- Victoria's Secret price target lowered to $71 from $86 at JPMorgan
- 06/02/22 Baird
- Ambarella price target lowered to $125 from $200 at Baird
- 06/01/22 Craig-Hallum
- Ambarella price target lowered to $100 from $170 at Craig-Hallum
- 06/01/22 Needham
- Ambarella price target lowered to $120 from $175 at Needham
- 06/01/22 Morgan Stanley
- Ambarella price target lowered to $114 from $122 at Morgan Stanley
- 06/01/22 Craig-Hallum
- Digital Turbine price target lowered to $85 from $105 at Craig-Hallum
- 06/01/22 Oppenheimer
- Digital Turbine price target lowered to $40 from $117 at Oppenheimer
- 02/16/22 Roth Capital
- Roth says Google news creates more unwarranted noise around Digital Turbine
- 05/26/22 Bernstein
- Humana resumed with a Market Perform at Bernstein
- 04/28/22 Wells Fargo
- Humana price target raised to $512 from $491 at Wells Fargo
- 04/13/22 UBS
- Humana upgraded to Buy from Neutral at UBS
- 04/07/22 Truist
- Humana price target raised to $490 from $460 at Truist
- 05/11/22 Cowen
- CareMax price target lowered to $8 from $11 at Cowen
- 01/07/22 UBS
- CareMax initiated with a Buy at UBS
- 12/01/21 Piper Sandler
- Piper Sandler remains buyer of CareMax after management meeting
- 11/15/21 Piper Sandler
- Piper remains buyer of CareMax, likes share setup into Q4
- 05/23/22 Mizuho
- Nio could be back to pre-shutdown levels by June, says Mizuho
- 05/16/22 BofA
- Nio upgraded to Buy at BofA on 'brighter' second half view
- 05/16/22 BofA
- Nio upgraded to Buy from Neutral at BofA
- 05/02/22 Morgan Stanley
- Nio's April sales 'crimped' by lockdowns, says Morgan Stanley
- 06/02/22 Stifel
- Levi Strauss price target lowered to $26 from $30 at Stifel
- 04/11/22 JPMorgan
- Levi Strauss price target lowered to $27 from $32 at JPMorgan
- 04/07/22 UBS
- Levi Strauss price target lowered to $34 from $37 at UBS
- 04/07/22 Citi
- Levi Strauss price target lowered to $27 from $28 at Citi
- $150.02 /
-4.775 (-3.08%) - 05/27/22 Morgan Stanley
- AmerisourceBergen target lowered to $175 at Morgan Stanley ahead of analyst day
- 05/26/22 Barclays
- AmerisourceBergen upgraded to Overweight from Equal Weight at Barclays
- 05/25/22 Deutsche Bank
- AmerisourceBergen price target lowered to $167 from $168 at Deutsche Bank
- 05/05/22 Baird
- AmerisourceBergen price target raised to $187 from $179 at Baird
- 05/31/22
- Victoria's Secret sees Q2 EPS 95c-$1.25 , consensus $1.19
- 05/31/22
- Victoria's Secret reports Q1 EPS $1.11, consensus 84c
- 03/02/22
- Victoria's Secret sees FY22 revenue flat to up low-single digits
VRTX Vertex Pharmaceuticals - 05/05/22
- Vertex Pharmaceuticals reports Q1 adjusted EPS $3.52, consensus $3.49
- 05/05/22
- Notable companies reporting after market close
- 01/26/22
- Vertex Pharmaceuticals reports Q4 EPS $3.37, consensus $3.29
- 01/26/22
- Notable companies reporting after market close
- 04/28/22
- Twitter withdrawing previously provided outlook given pending acquisition
- 04/28/22
- Twitter reports Q1 EPS 90c, consensus 3c
- 02/10/22
- Twitter expects FY22 revenue growth in low to mid 20's range
- 02/10/22
- Twitter sees Q1 revenue $1.17B-$1.27B, consensus $1.26B
- $740.48 /
-17.53 (-2.31%) - 04/20/22
- Tesla reports Q1 EPS $3.22, consensus $2.26
- 04/20/22
- Notable companies reporting after market close
- 01/26/22
- Tesla reports Q4 non-GAAP EPS $2.54, consensus $2.26
- 04/28/22
- Tempur Sealy cuts FY22 EPS view to $3.20-$3.40 from $3.65-$3.85
- 04/28/22
- Tempur Sealy reports Q1 adjusted EPS 64c, consensus 60c
- 04/27/22
- Notable companies reporting before tomorrow's open
- 05/05/22
- Block reports Q1 adjusted EPS 18c, consensus 21c
- 02/24/22
- Block reports Q4 adjusted EPS 27c, consensus 22c
- 02/24/22
- Notable companies reporting after market close
- $332.10 /
-17.85 (-5.10%) - 06/01/22
- S&P Global suspends FY22 guidance, cites weak market conditions
- 05/03/22
- S&P Global cuts FY22 adjusted EPS view to $13.00-$13.25 from $13.30-$13.50
- 05/03/22
- S&P Global reports Q1 adjusted EPS $2.89, consensus $2.98
- 05/02/22
- Notable companies reporting before tomorrow's open
- 03/24/22
- Nio sees Q1 revenue $1.51B-$1.57B, consensus $1.66B
- 03/24/22
- Nio reports Q4 EPS (21c), consensus (21c)
- 05/26/22
- Medtronic sees Q1 organic revenue down 4.5%-5.5%, consensus $8.14B
- 05/26/22
- Medtronic sees Q1 EPS $1.10-$1.14, consensus $1.40
- 05/26/22
- Medtronic sees FY23 EPS $5.53-$5.65, consensus $5.82
- 05/26/22
- Medtronic reports Q4 EPS $1.52, consensus $1.56
- 06/01/22
- Levi Strauss says 6%-8% annual net revenue growth target up from 4%-6% view
- 06/01/22
- Levi Strauss backs FY22 adjusted EPS view of $1.50-$1.56, consensus $1.55
- 06/01/22
- Levi Strauss sees 2027 revenue $9B-$10B, reflecting 6-8% organic annual growth
- 04/06/22
- Levi Strauss backs FY22 adjusted EPS $1.50-$1.56, consensus $1.55
- 06/01/22
- Humana backs FY22 adjusted EPS view of about $24.50, consensus $24.63
- 04/27/22
- Humana raises FY22 adjusted EPS view to 'approximately $24.50'
- 04/27/22
- Humana reports Q1 adjusted EPS $8.04, consensus $6.78
- 02/02/22
- Humana sees FY22 adjusted EPS at least $24.00, consensus $23.85
- 05/31/22
- HP Inc. raises FY22 EPS view to $4.24-$4.38 from $4.18-$4.38, consensus $4.25
- 05/31/22
- HP Inc. sees Q3 EPS $1.03-$1.08, consensus $1.02
- 05/31/22
- HP Inc. reports Q2 EPS $1.08, consensus $1.05
- 05/31/22
- Notable companies reporting after market close
- 05/09/22
- GoodRx sees Q2 revenue about $190M, consensus $215.62M
- 05/09/22
- GoodRx reports Q1 adjusted EPS 10c, consensus 8c
- 05/09/22
- Notable companies reporting after market close
- 02/28/22
- GoodRx sees FY22 revenue growth roughly 23%, consensus $1.02B
- $188.59 /
-4.965 (-2.57%) - 04/27/22
- Meta sees Q2 revenue $28B-$30B, consensus $30.63B
- 04/27/22
- Meta Platforms reports Q1 EPS $2.72, consensus $2.56
- 04/27/22
- Notable companies reporting after market close
- 02/02/22
- Meta sees Q1 revenue $27B-29B, consensus $30.14B
- 06/01/22
- Delta Air Lines sees Q2 revenue $12.4B-$12.5B, consensus $12.93B
- 04/13/22
- Delta Air Lines sees Q2 revenue 93%-97%, consensus $11.54B
- 04/13/22
- Delta Air Lines reports Q1 adjusted EPS ($1.23), consensus ($1.27)
- 04/12/22
- Notable companies reporting before tomorrow's open
- $176.04 /
+15.44 (+9.61%) - 05/31/22
- Salesforce jumps 5.5% to $169.12 after Q1 earnings beat
- 05/31/22
- Salesforce cuts FY23 revenue view to $31.7B-$31.8B, consensus $32.06B
- 05/31/22
- Salesforce sees Q2 revenue $7.69B-$7.70B, consensus $7.77B
- 05/31/22
- Salesforce sees FY23 EPS $4.74-$4.76, consensus $4.65
- 06/01/22
- Capri Holdings provides quarterly FY23 guidance
- 06/01/22
- Capri Holdings sees Q1 EPS $1.35, consensus $1.45
- 06/01/22
- Capri Holdings sees FY23 EPS $6.85, consensus $6.57
- 06/01/22
- Capri Holdings reports Q4 adjusted EPS $1.02, consensus 82c
- 03/08/22
- CareMax sees FY22 revenue $540M-$560M, consensus $590.47M
- 03/08/22
- CareMax reports Q4 GAAP EPS (4c), consensus (6c)
- 05/03/22
- Blueprint Medicines sees FY22 revenue $180M-$200M, consensus $192.34M
- 05/03/22
- Blueprint Medicines reports Q1 EPS ($1.79), consensus ($1.86)
- 02/16/22
- Blueprint Medicines sees 2022 revenue $180M-$200M, consensus $210.91M
- 02/16/22
- Blueprint Medicines reports Q4 EPS ($5.40), consensus ($1.65)
- 05/31/22
- Digital Turbine sees Q1 non-GAAP EPS 34c-35c, consensus 44c
- 05/31/22
- Digital Turbine reports Q4 non-GAAP EPS 39c, consensus 39c
- 05/17/22
- Digital Turbine reaffirms FY22 non-GAAP EPS $1.66-$1.68, consensus $1.67
- 02/08/22
- Digital Turbine sees FY22 non-GAAP EPS $1.66-$1.68, consensus $1.60
- 05/31/22
- Ambarella sees Q2 revenue $78M-$82M, consensus $91.48M
- 05/31/22
- Ambarella reports Q1 EPS 44c, consensus 36c
- 03/01/22
- Ambarella sees Q1 revenue $88.5M-$91.5M, consensus $90.7M
- 05/12/22
- Affirm raises FY22 revenue view to $1.33B-$1.34B from at least $1.31B
- 05/12/22
- Affirm sees Q4 revenue $345M-$355M, consensus $351.88M
- 05/12/22
- Affirm reports Q3 EPS (19c), consensus (54c)
- 05/12/22
- Notable companies reporting after market close
- $150.02 /
-4.775 (-3.08%) - 06/01/22
- AmerisourceBergen guides to long-term adjusted EPS growth of 8%-12%
- 06/01/22
- AmerisourceBergen backs FY22 adjusted EPS view $10.80-$11.05, consensus $10.95
- 05/04/22
- AmerisourceBergen raises FY22 adjusted EPS view to $10.80-$11.05
- 05/04/22
- AmerisourceBergen reports Q2 adjusted EPS $3.22, consensus $2.93
- 04/28/22
- Apple says y/y Q3 revenue growth to be impacted by COVID
- 04/28/22
- Apple reports Q2 EPS $1.52, consensus $1.43
- 04/28/22
- Notable companies reporting after market close
- 02/27/22
- Berkshire operating earnings surge, Buffett repurchases record $27B in stock
VRTX Vertex Pharmaceuticals - 01/08/22
- Biotech due to bounce back, Vertex stands out, Barron's says
- 05/31/22
- U.S. Supreme Court suspends Texas social media law, Bloomberg reports
- 05/26/22
- Twitter investors vote to remove Silver Lake's Durban from board, CNBC reports
- 05/25/22
- Jack Dorsey stepping down from Twitter board, Axios reports
- $740.48 /
-17.53 (-2.31%) - 06/01/22
- Tesla CEO Musk demands executives return to the office, Bloomberg reports
- 05/30/22
- Tesla Shanghai plant restores weekly output to 70%, Reuters reports
- 05/27/22
- SEC looks into Elon Musk's early Twitter stake, Reuters reports
- 05/27/22
- NHTSA seeks information from Tesla on Canadian fire incident, Reuters reports
- 03/03/22
- Shake Shack offers bitcoin as reward for Cash App users, WSJ reports
- 01/27/22
- Apple working to turn iPhones into payment terminals, Bloomberg reports
OPA Magnum Opus Acquisition - 05/31/22
- Forbes cancels plan to go public view Magnum Opus SPAC, NYT says
- 05/31/22
- Nio may look to set up production in U.S., DigiTimes reports
- 04/10/22
- Nio suspends production due to supply chain disruptions, Reuters reports
- 04/05/22
- Nio in discussions on licensing battery-swapping technology, FT reports
- 02/23/22
- Nio plans to make own phones to interact with its cars, DigiTimes reports
- 05/25/22
- Zuckerberg's Metaverse to lose money in 'near term,' Bloomberg says
- 05/05/22
- Meta announces sharp slowdown in hiring, WSJ reports
- 04/21/22
- Meta's Sandberg probed for getting tabloid to pass on Kotick story, WSJ says
- 02/05/22
- Medtronic stock can gain 20% as COVID subsides, Barron's says
- 04/04/22
- JCPenney's new CEO Rosen not chasing new customers, WSJ reports
- 04/21/22
- Humana in talks to sell arm of its Kindred at Home to CD&R, Bloomberg reports
- 01/11/22
- Insurers to cover rapid Covid-19 tests under White House plan, WSJ reports
- 04/23/22
- Merck, CVS among dividend stocks to help whip inflation now, Barron's says
- 04/09/22
- HP stock gets a Buffett boost, still 'a screaming buy,' Barron's says
- 03/30/22
- TSMC says demand for consumer electronics starting to slow, Nikkei Asia reports
- 01/28/22
- HP wins fraud case in U.K. over Autonomy acquisition, CNBC says
- $188.59 /
-4.965 (-2.57%) - 06/01/22
- Sandberg stepping down as Meta Platforms' COO, Bloomberg reports
- 05/28/22
- Alphabet, Meta among bargain stocks to buy now, Barron's says
ENOB Enochian Biosciences - 06/01/22
- Enochian Biosciences sinks after Hindenburg calls 'scam' in report
- 06/01/22
- Hindenburg Research announces short position in Enochian Biosciences
- 05/27/22
- Delta cutting flights to relieve pressure on operations, Bloomberg reports
- 04/26/22
- Delta to begin paying flight attendants during boarding, CNBC says
- 04/21/22
- Delta, United to end restrictions on flyers banned over mask violations, FT says
- 04/21/22
- DOJ appeals transportation mask mandate ruling, NYT reports
- $176.04 /
+15.44 (+9.61%) - 03/05/22
- Cloud stocks have become a haven in tech, Barron's says
- 06/01/22
- 'Buy now, pay later' companies impacted by late payments, losses, WSJ reports
- 05/19/22
- Klarna looks to raise up to $1B at lower valuation, WSJ reports
- 03/14/22
- Affirm halts bond sale because of market volatility, Bloomberg reports
- 12/16/21
- CFPB to seek buy now, pay later information from Affirm, others, Bloomberg says
- $150.02 /
-4.775 (-3.08%) - 02/01/22
- J&J, distributors to pay $590M to settle tribes' opioid claims, Bloomberg says
- 06/01/22
- Apple to move some iPad production out of China, Nikkei Asia reports
- 05/31/22
- Kuo thinks new iPhone A16 chip to keep using 5nm process, 9to5Mac reports
- 05/27/22
- Big tech firms lobbying attempts at privacy regulation, The Markup reports
- 05/26/22
- Production of Apple's iPhone 14 Max 'weeks' behind schedule, MacRumors reports
VRTX Vertex Pharmaceuticals - 05/23/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- $740.48 /
-17.53 (-2.31%) - 05/31/22
- What You Missed This Week in EVs and Clean Energy
- 06/01/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 04/28/22
- Fly Intel: Pre-market Movers
- 05/13/22
- Proven algorithm says sell these stocks now
- 05/13/22
- Here's What You Missed in Crypto This Week
- $332.10 /
-17.85 (-5.10%) - 06/01/22
- What You Missed On Wall Street On Wednesday
- 06/01/22
- What You Missed On Wall Street This Morning
- 06/01/22
- Fly Intel: Pre-market Movers
- 03/02/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
OPA Magnum Opus Acquisition - 03/06/22
- Week in SPAC News: Graf IV said in talks with Urgently
- 02/13/22
- Week in SPAC News: Quantum computing company D-Wave to merge with DPCM Capital
- 05/31/22
- What You Missed On Wall Street On Tuesday
- 05/31/22
- What You Missed On Wall Street This Morning
- 05/23/22
- Fly Intel: After-Hours Movers
- 04/27/22
- Fly Intel: After-Hours Movers
- 05/27/22
- What You Missed On Wall Street This Morning
- 05/09/22
- Fly Insider: Kennametal, Apple among notable insider trades this week
- 04/07/22
- What You Missed On Wall Street On Thursday
- 04/07/22
- What You Missed On Wall Street This Morning
- 04/13/22
- What You Missed On Wall Street On Wednesday
- 04/13/22
- What You Missed On Wall Street This Morning
- 05/23/22
- What You Missed On Wall Street On Monday
- 05/10/22
- What You Missed On Wall Street On Tuesday
- $188.59 /
-4.965 (-2.57%) - 05/25/22
- #SocialStocks: Jack Dorsey steps down from Twitter board, makes room for Musk
- 04/21/22
- What You Missed On Wall Street On Thursday
- $176.04 /
+15.44 (+9.61%) - 05/31/22
- Fly Intel: After-Hours Movers
- 03/15/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 05/13/22
- What You Missed On Wall Street On Friday
- 05/13/22
- What You Missed On Wall Street This Morning
- $150.02 /
-4.775 (-3.08%) - 05/26/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 05/11/22
- Fly Intel: After-Hours Movers
- 04/12/22
- What You Missed On Wall Street On Tuesday
- 06/01/22
- #SocialStocks: Supreme Court strikes down Texas social media law for now
- 05/26/22
- What You Missed On Wall Street On Thursday
- 05/31/22
- Victoria's Secret options imply 12.5% move in share price post-earnings
VRTX Vertex Pharmaceuticals - 01/10/22
- Early notable gainers among liquid option names on January 10th
- 05/18/22
- Notable open interest changes for May 18th
- 05/17/22
- Notable open interest changes for May 17th
- 05/16/22
- Notable open interest changes for May 16th
- $740.48 /
-17.53 (-2.31%) - 05/23/22
- Notable open interest changes for May 23rd
- 05/19/22
- Notable open interest changes for May 19th
- 03/23/22
- Tempur Sealy put volume heavy and directionally bearish
- 02/28/22
- Tempur Sealy call volume above normal and directionally bullish
- 05/05/22
- Square options imply 10.3% move in share price post-earnings
- 03/23/22
- Square put volume heavy and directionally bearish
- 03/07/22
- Square put volume heavy and directionally bearish
- 02/22/22
- Square put buyer realizes 12% same-day gains
- $332.10 /
-17.85 (-5.10%) - 03/02/22
- Unusually active option classes on open March 2nd
- 05/11/22
- Unusually active option classes on open May 11th
- 06/01/22
- NIO call volume above normal and directionally bullish
- 06/01/22
- Unusually active option classes on open June 1st
- 05/20/22
- Unusually active option classes on open May 20th
- 05/09/22
- Notable open interest changes for May 9th
- 01/31/22
- Two new option listings and three option delistings on January 31st
- 12/30/21
- Largest borrow rate increases among liquid names
- 04/27/22
- Medtronic put volume heavy and directionally bearish
- 01/31/22
- Medtronic put volume heavy and directionally bearish
- 12/16/21
- Medtronic put volume heavy and directionally bearish
- 04/11/22
- Levi Strauss put volume heavy and directionally bearish
- 04/06/22
- Levi Strauss options imply 7.2% move in share price post-earnings
- 01/26/22
- Levi Strauss options imply 6.7% move in share price post-earnings
- 02/03/22
- Early notable gainers among liquid option names on February 3rd
- 01/12/22
- Unusually active option classes on open January 12th
- 05/31/22
- HP Inc. options imply 7.2% move in share price post-earnings
- 05/27/22
- Early notable gainers among liquid option names on May 27th
- 05/24/22
- HP Inc. put volume heavy and directionally bearish
- 04/29/22
- HP Inc. put volume heavy and directionally bearish
- 05/09/22
- GoodRx Holdings options imply 17.9% move in share price post-earnings
- $188.59 /
-4.965 (-2.57%) - 05/05/22
- Facebook call buyer realizes 131% same-day gains
- 05/02/22
- Early notable gainers among liquid option names on May 2nd
- 04/29/22
- Notable open interest changes for April 29th
- 05/31/22
- Delta Air Lines put volume heavy and directionally bearish
- 05/27/22
- Unusually active option classes on open May 27th
- 05/24/22
- Unusually active option classes on open May 24th
- 04/26/22
- Delta Air Lines put volume heavy and directionally bearish
- $176.04 /
+15.44 (+9.61%) - 06/01/22
- Early notable gainers among liquid option names on June 1st
- 05/31/22
- Salesforce options imply 7.6% move in share price post-earnings
- 05/31/22
- Unusually active option classes on open May 31st
- 02/23/22
- Salesforce call volume above normal and directionally bullish
- 04/27/22
- Capri Holdings put volume heavy and directionally bearish
- 04/07/22
- Capri Holdings call volume above normal and directionally bullish
- 03/04/22
- Capri Holdings put volume heavy and directionally bearish
- 03/03/22
- Capri Holdings put volume heavy and directionally bearish
- 05/31/22
- Digital Turbine options imply 14.6% move in share price post-earnings
- 05/16/22
- Digital Turbine call volume above normal and directionally bullish
- 05/10/22
- Digital Turbine call volume above normal and directionally bullish
- 04/25/22
- Digital Turbine call volume above normal and directionally bullish
- 05/31/22
- Ambarella options imply 14.2% move in share price post-earnings
- 05/13/22
- Notable open interest changes for May 13th
- 05/12/22
- Affirm Holdings options imply 29.7% move in share price post-earnings
- 04/25/22
- Affirm Holdings call volume above normal and directionally bullish
- 04/22/22
- Affirm Holdings call volume above normal and directionally bullish
- 06/01/22
- Notable open interest changes for June 1st
- 05/31/22
- Notable open interest changes for May 31st
- 05/27/22
- Notable open interest changes for May 27th
- 05/24/22
- Notable open interest changes for May 24th
|
On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< - 06/01/22
- Victoria's Secret rises 8.9%
- 05/26/22
- Victoria's Secret launches VS&Co-Lab digital platform
- 04/29/22
- Victoria's Secret & PINK Beauty launch in Amazon's store
VRTX Vertex Pharmaceuticals - 05/23/22
- Catalyst Biosciences sells complement portfolio for $60M
- 05/18/22
- Vertex Pharmaceuticals appoints Suketu Upadhyay to board of directors
- 05/17/22
- Vertex Pharmaceuticals announces expansion plans in Boston's Seaport
- 05/05/22
- Vertex Pharmaceuticals still sees FY22 product revenues $8.4B-$8.6B
- 05/27/22
- Twitter board does not accept resignation of Silver Lake's Egon Durban
- 05/25/22
- Twitter up 9% after Elon Musk files amended 13D related to takeover agreement
- 05/25/22
- Musk commits to provide additional $6.25B in equity financing for Twitter deal
- 05/20/22
- Elon Musk: We will never surrender/settle an unjust case against us
- $737.88 /
-20.13 (-2.66%) - 05/30/22
- Fly Intel: Top five weekend stock stories
- 05/30/22
- Musk says Bill Gates has 'multi-billion dollar' Tesla short position
- 05/24/22
- Cathie Wood's ARK Investment bought 26.1K shares of Tesla today
- 05/23/22
- Cathie Wood's ARK Investment bought 15.9K shares of Tesla today
- 02/22/22
- Tempur Sealy falls -16.5%
- 02/22/22
- Tempur Sealy falls -13.0%
- 02/22/22
- Tempur Sealy falls -12.9%
- 02/22/22
- Tempur Sealy increases quarterly dividend to 10c per share
- 05/25/22
- Cathie Wood's ARK Investment bought 24.4K shares of Block today
- 05/24/22
- Cathie Wood's ARK Investment bought 222.3K shares of Block today
- 05/18/22
- Square acquires GoParrot digital ordering and marketing platform for restaurants
- 05/17/22
- Square expands Afterpay integration to in-person points of sale
- $337.39 /
-12.56 (-3.59%) - 06/01/22
- S&P Global falls -9.3%
- 04/13/22
- S&P Global names Daniel Yergin vice chairman
- 04/04/22
- S&P Global to sell LCD business to Morningstar for $650M in cash
- 03/21/22
- S&P Global Ratings to withdraw ratings on Russian entities
- 06/01/22
- RedBall Acquisition, SeatGeek agree to terminate combination agreement
- 06/01/22
- RedBall Acquisition, SeatGeek agree to terminate combination agreement
OPA Magnum Opus Acquisition - 06/01/22
- Forbes Global Media ends SPAC deal with Magnum Opus Acquisition
- 04/11/22
- Forbes unveils preview of virtual Billionaires NFT collection
- 02/10/22
- Forbes and SPAC Magnum Opus announce Binance pact for Forbes to be listed
- 06/01/22
- NIO delivers 7,024 vehicles in May
- 05/20/22
- Nio up 7% in pre-market after company announced Singapore exchange listing
- 05/05/22
- Nio provides update on HFCAA status
- 05/01/22
- Nio delivers 5,074 vehicles in April 2022
- 05/31/22
- Meta Platforms to change ticker symbol to 'META' on June 9
- 05/20/22
- WhatsApp announces new products for business messaging
- 05/10/22
- Instagram debuts Digital Collectibles to showcase NFTs
- 05/03/22
- Instagram is testing a full-screen home feed
- 05/26/22
- Medtronic: Q1 EPS guidance includes FX headwind of about 5c
- 05/26/22
- Medtronic: Procedure volumes in most markets reached pre-Covid levels by Q4E
- 05/26/22
- Medtronic sees 'strong' improvement in 2H23, pipeline 'robust'
- 05/26/22
- Medtronic: Parts of quarter played out as anticipated, but unexpected challenges
- 05/06/22
- Autohome appoints Craig Yan Zeng as CFO
- 05/05/22
- LexinFintech updates status under HFCAA
- 03/16/22
- LexinFintech announces $50M share repurchase program
- 05/13/22
- Starboard takes stake in Humana, exits System1
- 05/03/22
- Kala announces new commercial, Medicare coverage for EYSUVIS
- 04/21/22
- Humana to divest interest in Hospice, Personal Care divisions of KAH Hospice
- 02/22/22
- Humana to add two new independent directors in Starboard cooperation agreement
- 05/31/22
- HP Inc. CEO: Supply chain situation continues to be challenging
- 05/27/22
- Poly not providing FY23 guidance
- 05/23/22
- HP Inc. names Ernest Nicolas as chief supply chain officer
- 05/19/22
- HP Inc. debuts new HP Spectre, HP Envy laptops
- 05/17/22
- GoodRx announces strategic relationship with RxVantage
- 05/09/22
- GoodRx 'unlikely' to achieve guidance provided on Q4 earnings call
- 05/09/22
- GoodRx names former Uber grocery, new verticals chief Raj Beri as COO
- 05/02/22
- GoodRx partners with AssistRx
- $193.20 /
-0.355 (-0.18%) - 05/27/22
- Immersion files patent infringement complaint against Meta Platforms
- 05/25/22
- Microsoft says Meta selected Azure as strategic cloud provider
ENOB Enochian Biosciences - 05/25/22
- Enochian Biosciences says Gumrukcu 'has had no formal role in the company'
- 05/25/22
- Enochian BioSciences falls after Gumrukcu charged in murder-for-hire conspiracy
- 05/25/22
- Enochian Biosciences trading resumes
- 05/25/22
- Enochian Biosciences trading halted, volatility trading pause
- 06/01/22
- Delta jumps 2.5% in premarket trading after providing updated Q2 guidance
- 06/01/22
- Delta sees June quarter total unit revenues 7-8 pts better than expected
- 06/01/22
- Delta Air Lines sees June quarter revenue 'fully restored' to 2019
- 04/19/22
- DOJ to appeal ruling that lifted COVID mask mandate on travel
- $176.91 /
+16.31 (+10.16%) - 06/01/22
- Salesforce rises 10.3%
- 06/01/22
- Salesforce rises 13.3%
- 06/01/22
- Salesforce rises 11.6%
- 05/31/22
- Salesforce co-CEO Benioff: It was a remarkably healthy quarter
- 06/01/22
- Capri Holdings jumps 8% to $52.80 after Q4 results, FY23 guidance top estimates
- 06/01/22
- Capri Holdings announces new $1B share repurchase program
- 05/16/22
- David Einhorn's Greenlight adds Southwestern, exits Sonos in Q1
- 03/21/22
- Capri Holdings appoints Emmanuel Gintzburger CEO of Versace
- 06/01/22
- CareMax to acquire Medicare value-based care business of Steward Health Care
- 02/07/22
- CareMax names Jose Rodriguez as Chair of board of directors
- 05/02/22
- Roivant Sciences announces collaborations in targeted protein degradation
- 04/08/22
- Blueprint Medicines says SYMPHONY results support development expansion
- 03/25/22
- Blueprint Medicines' AYVAKYT receives EC approval for expanded indication
- 02/28/22
- Blueprint Medicines, Proteovant Therapeutics announces strategic collaboration
- 06/01/22
- Bitfarms reports average production in May 13.9 bitcoin/day
- 05/26/22
- Bitfarms to host Analyst, Institutional Investor Day on June 22
- 05/16/22
- Bitfarms announces 2022 expansion plan update
- 05/02/22
- Bitfarms mines 405 bitcoin in April
- 06/01/22
- Bark falls 10% after Q4 results miss expectations
- 05/11/22
- Original Bark Company names Cindy Gustafson as Chief Marketing Officer
- 01/11/22
- Original Bark Company rises 21.7%
- 01/10/22
- Bark executive chairman Matt Meeker to become CEO
- 05/31/22
- Digital Turbine delays 10-K filing
- 05/17/22
- Digital Turbine says FY22 quarterly results to be restated
- 04/27/22
- Digital Turbine enters multiyear partnership with AccuWeather
- 02/16/22
- Google announces 'Privacy Sandbox on Android'
- 04/05/22
- Lumentum, Ambarella announce a new joint reference design Vision-D
- 03/28/22
- Ambarella hires new CFO, Brian White, formerly with Maxim Integrated Products
- 03/21/22
- Ambarella announces passing of CFO Casey Eichler
- 03/16/22
- Ambarella, Helm.ai announce ADAS software integration
- 05/24/22
- WooCommerce and Affirm expand partnership with Canada launch
- 05/12/22
- Affirm CEO: Our underlying business is performing very well
- 05/12/22
- Affirm jumps 22% to $21.97 after Q3 results beat, FY22 guidance raised
- 05/12/22
- Affirm extends multi-year partnership with Shopify in U.S.
- 05/25/22
- Luminar hires CJ Moore from Apple, Taner Ozcelik for technical team
- 05/25/22
- Luminar up 4% to $8.80 after Bloomberg report of Apple hire
- 05/16/22
- Berkshire Hathaway adds Citi, exits Wells Fargo in Q1
- 05/16/22
- Soros Capital buys Suncor and Mosaic during Q1, exits Alphabet
- $176.91 /
+16.31 (+10.16%) - 06/01/22 RBC Capital
- Salesforce margin outlook overshadowed lower revenue guide, says RBC Capital
- 06/01/22 BMO Capital
- Salesforce price target lowered to $225 from $260 at BMO Capital
- 06/01/22 Stifel
- Salesforce price target lowered to $250 from $300 at Stifel
- 06/01/22 Deutsche Bank
- Salesforce price target lowered to $260 from $300 at Deutsche Bank
- 06/01/22 Morgan Stanley
- Morgan Stanley stays Underweight on HP Inc. after Q2 report
- 06/01/22 Citi
- HP Inc. price target raised to $40 from $38 at Citi
- 06/01/22 Barclays
- HP Inc. price target raised to $32 from $29 at Barclays
- 05/25/22 JPMorgan
- HP Inc. price target lowered to $39 from $41 at JPMorgan
- $337.39 /
-12.56 (-3.59%) - 05/04/22 BMO Capital
- S&P Global price target lowered to $433 from $462 at BMO Capital
- 05/04/22 Deutsche Bank
- S&P Global price target lowered to $483 from $515 at Deutsche Bank
- 05/04/22 Credit Suisse
- S&P Global price target lowered to $425 from $495 at Credit Suisse
- 05/04/22 UBS
- S&P Global price target lowered to $441 from $486 at UBS
- 06/01/22 Goldman Sachs
- Delta Air Lines price target raised to $45 from $44 at Goldman Sachs
- 04/26/22 Northland
- SpaceX's Starlink deal with Hawaiian highlights risk for Gogo, says Northland
- 04/22/22 Morgan Stanley
- United Airlines price target raised to $67 from $62 at Morgan Stanley
- 04/22/22 JPMorgan
- Delta Air Lines price target raised to $70 from $69 at JPMorgan
OPA Magnum Opus Acquisition - 03/01/22 Benchmark
- Magnum Opus Acquisition initiated with a Buy at Benchmark
- 12/15/21 Cantor Fitzgerald
- Magnum Opus Acquisition price target raised to $14.50 from $10.00 at Cantor Fitzgerald
- 10/21/21 Cantor Fitzgerald
- Magnum Opus Acquisition initiated with an Overweight at Cantor Fitzgerald
- 06/01/22 Piper Sandler
- Tempur Sealy downgraded to Neutral from Overweight at Piper Sandler
- 04/12/22 Loop Capital
- Tempur Sealy price target lowered to $28 from $35 at Loop Capital
- 04/06/22 Raymond James
- Tempur Sealy price target lowered to $38 from $45 at Raymond James
- 04/01/22 Piper Sandler
- Tempur Sealy price target lowered to $34 from $40 at Piper Sandler
VRTX Vertex Pharmaceuticals - 06/01/22 Maxim
- Maxim upgrades Vertex Pharmaceuticals to Buy as company expands beyond CF
- 06/01/22 Maxim
- Vertex Pharmaceuticals upgraded to Buy from Hold at Maxim
- 05/23/22 Piper Sandler
- Piper Sandler remains bullish on Catalyst after sale of complement portfolio
- 05/23/22 SVB Leerink
- Vertex Pharmaceuticals initiated with a Market Perform at SVB Leerink
- 06/01/22 Jefferies
- Blueprint Medicines raised to Buy at Jefferies after survey on Ayvakit in ISM
- 06/01/22 Jefferies
- Blueprint Medicines upgraded to Buy from Hold at Jefferies
- 05/18/22 Piper Sandler
- Blueprint Medicines price target lowered to $65 from $84 at Piper Sandler
- 05/04/22 Baird
- Blueprint Medicines price target lowered to $96 from $123 at Baird
- 06/01/22 Baird
- Baird downgrades GoodRx to Neutral amid disruption at Kroger
- 06/01/22 Baird
- GoodRx downgraded to Neutral from Outperform at Baird
- 05/16/22 Baird
- Baird 'hypothesizing' GoodRx PBM/pharmacy issue at Kroger may be improving
- 05/12/22 Wells Fargo
- GoodRx price target lowered to $9 from $20 at Wells Fargo
- 06/01/22 Atlantic Equities
- Medtronic downgraded to Neutral from Overweight at Atlantic Equities
- 05/31/22 Raymond James
- Medtronic price target lowered to $109 from $116 at Raymond James
- 05/31/22 Truist
- Medtronic price target lowered to $111 from $121 at Truist
- 05/27/22 RBC Capital
- Medtronic price target lowered to $122 from $135 at RBC Capital
- 06/01/22 Macquarie
- Digital Turbine price target lowered to $40 from $70 at Macquarie
- 05/27/22 JPMorgan
- iPhone China shipments in April below seasonal, says JPMorgan
- 05/25/22 Loop Capital
- Loop Capital sees consensus for Apple's iPhone revenue in second half as low
- 05/24/22 BofA
- Apple App Store growth has re-accelerated modestly, says BofA
ENOB Enochian Biosciences - 05/23/22 Mizuho
- April delinquency trends promising for Affirm, says Mizuho
- 05/17/22 Mizuho
- Affirm price target lowered to $50 from $79 at Mizuho
- 05/16/22 Barclays
- Affirm price target lowered to $35 from $65 at Barclays
- 05/13/22 RBC Capital
- Affirm price target lowered to $48 from $58 at RBC Capital
- 06/01/22 Piper Sandler
- App downloads for Block's Cash App strong, says Piper Sandler
- 05/24/22 Morgan Stanley
- Morgan Stanley upgrades Marqeta to Overweight on attractive entry point
- 05/23/22 Truist
- Block price target lowered to $145 from $165 at Truist
- 05/23/22 Deutsche Bank
- Block price target lowered to $155 from $180 at Deutsche Bank
- $737.88 /
-20.13 (-2.66%) - 06/01/22 Goldman Sachs
- Tesla price target lowered to $1,000 from $1,200 at Goldman Sachs
- 05/31/22 Mizuho
- Tesla shutdown in Shanghai a near-term headwind, says Mizuho
- 05/27/22 Credit Suisse
- Tesla pullback brings attractive entry point, says Credit Suisse
- 05/26/22 Jefferies
- Jefferies cuts Tesla price target on governance risk, challenging market
- 05/24/22 Jefferies
- Twitter price target lowered to $40 from $48 at Jefferies
- 05/24/22 Wedbush
- More fireworks expected heading into Twitter shareholder meeting, says Wedbush
- 05/24/22 KeyBanc
- Snap price target lowered to $27 from $45 at KeyBanc
- 05/24/22 Bernstein
- Bernstein says Tesla-Twitter saga far from over, discusses funding requirements
- 05/10/22 BMO Capital
- Yelp price target lowered to $37 from $42 at BMO Capital
- 04/06/22 DA Davidson
- System1 price target raised to $26 from $23 at DA Davidson
- 03/25/22 UBS
- Meta Platforms newsfeed changes and Reelz to drive higher monetization, says UBS
- $193.20 /
-0.355 (-0.18%) - 06/01/22 Morgan Stanley
- Meta Platforms price target lowered to $300 from $330 at Morgan Stanley
- 06/01/22 Morgan Stanley
- Meta Platforms price target lowered to $300 from $330 at Morgan Stanley
- 05/24/22 Jefferies
- Meta Platforms price target lowered to $310 from $330 at Jefferies
- 05/24/22 BofA
- Snap price target lowered to $30 from $50 at BofA
- 04/19/22 OTR Global
- Tapestry view downgraded to Mixed from Positive at OTR Global
- 04/19/22 Barclays
- Capri Holdings price target raised to $74 from $72 at Barclays
- 04/05/22 Wells Fargo
- Capri Holdings price target lowered to $85 from $95 at Wells Fargo
- 04/01/22 Barclays
- Capri Holdings price target lowered to $72 from $85 at Barclays
- 06/01/22 JPMorgan
- Victoria's Secret price target lowered to $57 from $71 at JPMorgan
- 06/01/22 Wells Fargo
- Victoria's Secret price target lowered to $60 from $70 at Wells Fargo
- 05/16/22 JPMorgan
- Victoria's Secret price target lowered to $71 from $86 at JPMorgan
- 04/05/22 Wells Fargo
- Victoria's Secret price target lowered to $70 from $75 at Wells Fargo
- 06/01/22 Craig-Hallum
- Ambarella price target lowered to $100 from $170 at Craig-Hallum
- 06/01/22 Needham
- Ambarella price target lowered to $120 from $175 at Needham
- 06/01/22 Morgan Stanley
- Ambarella price target lowered to $114 from $122 at Morgan Stanley
- 06/01/22 Cowen
- Ambarella price target lowered to $135 from $180 at Cowen
- 06/01/22 Craig-Hallum
- Digital Turbine price target lowered to $85 from $105 at Craig-Hallum
- 06/01/22 Oppenheimer
- Digital Turbine price target lowered to $40 from $117 at Oppenheimer
- 02/16/22 Roth Capital
- Roth says Google news creates more unwarranted noise around Digital Turbine
- 05/26/22 Bernstein
- Humana resumed with a Market Perform at Bernstein
- 04/28/22 Wells Fargo
- Humana price target raised to $512 from $491 at Wells Fargo
- 04/13/22 UBS
- Humana upgraded to Buy from Neutral at UBS
- 04/07/22 Truist
- Humana price target raised to $490 from $460 at Truist
- 05/11/22 Cowen
- CareMax price target lowered to $8 from $11 at Cowen
- 01/07/22 UBS
- CareMax initiated with a Buy at UBS
- 12/01/21 Piper Sandler
- Piper Sandler remains buyer of CareMax after management meeting
- 11/15/21 Piper Sandler
- Piper remains buyer of CareMax, likes share setup into Q4
- 05/23/22 Mizuho
- Nio could be back to pre-shutdown levels by June, says Mizuho
- 05/16/22 BofA
- Nio upgraded to Buy at BofA on 'brighter' second half view
- 05/16/22 BofA
- Nio upgraded to Buy from Neutral at BofA
- 05/02/22 Morgan Stanley
- Nio's April sales 'crimped' by lockdowns, says Morgan Stanley
- 06/01/22 Canaccord
- Original Bark Company price target lowered to $8 from $10 at Canaccord
- 02/11/22 Canaccord
- Original Bark Company price target lowered to $12 from $16 at Canaccord
- 11/18/21 Citi
- Original Bark Company price target lowered to $14 from $16 at Citi
- 06/28/21 Citi
- Original Bark Company initiated with a Buy at Citi
- 06/01/22 CLSA
- LexinFintech downgraded to Sell from Outperform at CLSA
- 05/31/22 Citi
- LexinFintech downgraded to Neutral from Buy at Citi
- 12/20/21 UBS
- LexinFintech downgraded to Neutral from Buy at UBS
- 08/26/21 DBS Bank
- LexinFintech downgraded to Hold from Buy at DBS Bank
- 05/31/22
- Victoria's Secret sees Q2 EPS 95c-$1.25 , consensus $1.19
- 05/31/22
- Victoria's Secret reports Q1 EPS $1.11, consensus 84c
- 03/02/22
- Victoria's Secret sees FY22 revenue flat to up low-single digits
VRTX Vertex Pharmaceuticals - 05/05/22
- Vertex Pharmaceuticals reports Q1 adjusted EPS $3.52, consensus $3.49
- 05/05/22
- Notable companies reporting after market close
- 01/26/22
- Vertex Pharmaceuticals reports Q4 EPS $3.37, consensus $3.29
- 01/26/22
- Notable companies reporting after market close
- 04/28/22
- Twitter withdrawing previously provided outlook given pending acquisition
- 04/28/22
- Twitter reports Q1 EPS 90c, consensus 3c
- 02/10/22
- Twitter expects FY22 revenue growth in low to mid 20's range
- 02/10/22
- Twitter sees Q1 revenue $1.17B-$1.27B, consensus $1.26B
- $737.88 /
-20.13 (-2.66%) - 04/20/22
- Tesla reports Q1 EPS $3.22, consensus $2.26
- 04/20/22
- Notable companies reporting after market close
- 01/26/22
- Tesla reports Q4 non-GAAP EPS $2.54, consensus $2.26
- 04/28/22
- Tempur Sealy cuts FY22 EPS view to $3.20-$3.40 from $3.65-$3.85
- 04/28/22
- Tempur Sealy reports Q1 adjusted EPS 64c, consensus 60c
- 04/27/22
- Notable companies reporting before tomorrow's open
- 05/05/22
- Block reports Q1 adjusted EPS 18c, consensus 21c
- 02/24/22
- Block reports Q4 adjusted EPS 27c, consensus 22c
- 02/24/22
- Notable companies reporting after market close
- $337.39 /
-12.56 (-3.59%) - 06/01/22
- S&P Global suspends FY22 guidance, cites weak market conditions
- 05/03/22
- S&P Global cuts FY22 adjusted EPS view to $13.00-$13.25 from $13.30-$13.50
- 05/03/22
- S&P Global reports Q1 adjusted EPS $2.89, consensus $2.98
- 05/02/22
- Notable companies reporting before tomorrow's open
- 03/24/22
- Nio sees Q1 revenue $1.51B-$1.57B, consensus $1.66B
- 03/24/22
- Nio reports Q4 EPS (21c), consensus (21c)
- 05/26/22
- Medtronic sees Q1 organic revenue down 4.5%-5.5%, consensus $8.14B
- 05/26/22
- Medtronic sees Q1 EPS $1.10-$1.14, consensus $1.40
- 05/26/22
- Medtronic sees FY23 EPS $5.53-$5.65, consensus $5.82
- 05/26/22
- Medtronic reports Q4 EPS $1.52, consensus $1.56
- 06/01/22
- Humana backs FY22 adjusted EPS view of about $24.50, consensus $24.63
- 04/27/22
- Humana raises FY22 adjusted EPS view to 'approximately $24.50'
- 04/27/22
- Humana reports Q1 adjusted EPS $8.04, consensus $6.78
- 02/02/22
- Humana sees FY22 adjusted EPS at least $24.00, consensus $23.85
- 05/31/22
- HP Inc. raises FY22 EPS view to $4.24-$4.38 from $4.18-$4.38, consensus $4.25
- 05/31/22
- HP Inc. sees Q3 EPS $1.03-$1.08, consensus $1.02
- 05/31/22
- HP Inc. reports Q2 EPS $1.08, consensus $1.05
- 05/31/22
- Notable companies reporting after market close
- 05/09/22
- GoodRx sees Q2 revenue about $190M, consensus $215.62M
- 05/09/22
- GoodRx reports Q1 adjusted EPS 10c, consensus 8c
- 05/09/22
- Notable companies reporting after market close
- 02/28/22
- GoodRx sees FY22 revenue growth roughly 23%, consensus $1.02B
- $193.20 /
-0.355 (-0.18%) - 04/27/22
- Meta sees Q2 revenue $28B-$30B, consensus $30.63B
- 04/27/22
- Meta Platforms reports Q1 EPS $2.72, consensus $2.56
- 04/27/22
- Notable companies reporting after market close
- 02/02/22
- Meta sees Q1 revenue $27B-29B, consensus $30.14B
- 06/01/22
- Delta Air Lines sees Q2 revenue $12.4B-$12.5B, consensus $12.93B
- 04/13/22
- Delta Air Lines sees Q2 revenue 93%-97%, consensus $11.54B
- 04/13/22
- Delta Air Lines reports Q1 adjusted EPS ($1.23), consensus ($1.27)
- 04/12/22
- Notable companies reporting before tomorrow's open
- $176.91 /
+16.31 (+10.16%) - 05/31/22
- Salesforce jumps 5.5% to $169.12 after Q1 earnings beat
- 05/31/22
- Salesforce cuts FY23 revenue view to $31.7B-$31.8B, consensus $32.06B
- 05/31/22
- Salesforce sees Q2 revenue $7.69B-$7.70B, consensus $7.77B
- 05/31/22
- Salesforce sees FY23 EPS $4.74-$4.76, consensus $4.65
- 06/01/22
- Capri Holdings provides quarterly FY23 guidance
- 06/01/22
- Capri Holdings sees Q1 EPS $1.35, consensus $1.45
- 06/01/22
- Capri Holdings sees FY23 EPS $6.85, consensus $6.57
- 06/01/22
- Capri Holdings reports Q4 adjusted EPS $1.02, consensus 82c
- 03/08/22
- CareMax sees FY22 revenue $540M-$560M, consensus $590.47M
- 03/08/22
- CareMax reports Q4 GAAP EPS (4c), consensus (6c)
- 05/03/22
- Blueprint Medicines sees FY22 revenue $180M-$200M, consensus $192.34M
- 05/03/22
- Blueprint Medicines reports Q1 EPS ($1.79), consensus ($1.86)
- 02/16/22
- Blueprint Medicines sees 2022 revenue $180M-$200M, consensus $210.91M
- 02/16/22
- Blueprint Medicines reports Q4 EPS ($5.40), consensus ($1.65)
- 05/16/22
- Bitfarms reports Q1 EPS 2c vs (6c) last year
- 03/28/22
- Bitfarms reports Q4 EPS 5c vs. (6c) last year
- 01/10/22
- Bark reports preliminary Q3 revenue $140M, two estimates $137.3MOriginal Bark Company
- 05/31/22
- Digital Turbine sees Q1 non-GAAP EPS 34c-35c, consensus 44c
- 05/31/22
- Digital Turbine reports Q4 non-GAAP EPS 39c, consensus 39c
- 05/17/22
- Digital Turbine reaffirms FY22 non-GAAP EPS $1.66-$1.68, consensus $1.67
- 02/08/22
- Digital Turbine sees FY22 non-GAAP EPS $1.66-$1.68, consensus $1.60
- 05/31/22
- Ambarella sees Q2 revenue $78M-$82M, consensus $91.48M
- 05/31/22
- Ambarella reports Q1 EPS 44c, consensus 36c
- 03/01/22
- Ambarella sees Q1 revenue $88.5M-$91.5M, consensus $90.7M
- 05/12/22
- Affirm raises FY22 revenue view to $1.33B-$1.34B from at least $1.31B
- 05/12/22
- Affirm sees Q4 revenue $345M-$355M, consensus $351.88M
- 05/12/22
- Affirm reports Q3 EPS (19c), consensus (54c)
- 05/12/22
- Notable companies reporting after market close
- 04/28/22
- Apple says y/y Q3 revenue growth to be impacted by COVID
- 04/28/22
- Apple reports Q2 EPS $1.52, consensus $1.43
- 04/28/22
- Notable companies reporting after market close
- 02/27/22
- Berkshire operating earnings surge, Buffett repurchases record $27B in stock
VRTX Vertex Pharmaceuticals - 01/08/22
- Biotech due to bounce back, Vertex stands out, Barron's says
- 05/31/22
- U.S. Supreme Court suspends Texas social media law, Bloomberg reports
- 05/26/22
- Twitter investors vote to remove Silver Lake's Durban from board, CNBC reports
- 05/25/22
- Jack Dorsey stepping down from Twitter board, Axios reports
- $737.88 /
-20.13 (-2.66%) - 06/01/22
- Tesla CEO Musk demands executives return to the office, Bloomberg reports
- 05/30/22
- Tesla Shanghai plant restores weekly output to 70%, Reuters reports
- 05/27/22
- SEC looks into Elon Musk's early Twitter stake, Reuters reports
- 05/27/22
- NHTSA seeks information from Tesla on Canadian fire incident, Reuters reports
- 03/03/22
- Shake Shack offers bitcoin as reward for Cash App users, WSJ reports
- 01/27/22
- Apple working to turn iPhones into payment terminals, Bloomberg reports
OPA Magnum Opus Acquisition - 05/31/22
- Forbes cancels plan to go public view Magnum Opus SPAC, NYT says
- 05/31/22
- Nio may look to set up production in U.S., DigiTimes reports
- 04/10/22
- Nio suspends production due to supply chain disruptions, Reuters reports
- 04/05/22
- Nio in discussions on licensing battery-swapping technology, FT reports
- 02/23/22
- Nio plans to make own phones to interact with its cars, DigiTimes reports
- 05/25/22
- Zuckerberg's Metaverse to lose money in 'near term,' Bloomberg says
- 05/05/22
- Meta announces sharp slowdown in hiring, WSJ reports
- 04/21/22
- Meta's Sandberg probed for getting tabloid to pass on Kotick story, WSJ says
- 02/05/22
- Medtronic stock can gain 20% as COVID subsides, Barron's says
- 04/21/22
- Humana in talks to sell arm of its Kindred at Home to CD&R, Bloomberg reports
- 01/11/22
- Insurers to cover rapid Covid-19 tests under White House plan, WSJ reports
- 04/23/22
- Merck, CVS among dividend stocks to help whip inflation now, Barron's says
- 04/09/22
- HP stock gets a Buffett boost, still 'a screaming buy,' Barron's says
- 03/30/22
- TSMC says demand for consumer electronics starting to slow, Nikkei Asia reports
- 01/28/22
- HP wins fraud case in U.K. over Autonomy acquisition, CNBC says
- $193.20 /
-0.355 (-0.18%) - 05/28/22
- Alphabet, Meta among bargain stocks to buy now, Barron's says
- 05/26/22
- Peter Thiel officially steps down from Meta board, Protocol reports
ENOB Enochian Biosciences - 06/01/22
- Enochian Biosciences sinks after Hindenburg calls 'scam' in report
- 06/01/22
- Hindenburg Research announces short position in Enochian Biosciences
- 05/27/22
- Delta cutting flights to relieve pressure on operations, Bloomberg reports
- 04/26/22
- Delta to begin paying flight attendants during boarding, CNBC says
- 04/21/22
- Delta, United to end restrictions on flyers banned over mask violations, FT says
- 04/21/22
- DOJ appeals transportation mask mandate ruling, NYT reports
- $176.91 /
+16.31 (+10.16%) - 03/05/22
- Cloud stocks have become a haven in tech, Barron's says
- 06/01/22
- 'Buy now, pay later' companies impacted by late payments, losses, WSJ reports
- 05/19/22
- Klarna looks to raise up to $1B at lower valuation, WSJ reports
- 03/14/22
- Affirm halts bond sale because of market volatility, Bloomberg reports
- 12/16/21
- CFPB to seek buy now, pay later information from Affirm, others, Bloomberg says
- 06/01/22
- Apple to move some iPad production out of China, Nikkei Asia reports
- 05/31/22
- Kuo thinks new iPhone A16 chip to keep using 5nm process, 9to5Mac reports
- 05/27/22
- Big tech firms lobbying attempts at privacy regulation, The Markup reports
- 05/26/22
- Production of Apple's iPhone 14 Max 'weeks' behind schedule, MacRumors reports
- 01/24/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/29/21
- Wall Street in Fives - Must Read Lists for Wednesday
VRTX Vertex Pharmaceuticals - 05/06/22
- What You Missed On Wall Street On Friday
- 05/06/22
- What You Missed On Wall Street This Morning
- $737.88 /
-20.13 (-2.66%) - 05/31/22
- What You Missed This Week in EVs and Clean Energy
- 05/27/22
- What You Missed On Wall Street On Friday
- 06/01/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 04/28/22
- Fly Intel: Pre-market Movers
- 03/31/22
- What You Missed On Wall Street On Thursday
- 03/31/22
- What You Missed On Wall Street This Morning
- 05/13/22
- Proven algorithm says sell these stocks now
- 05/13/22
- Here's What You Missed in Crypto This Week
- $337.39 /
-12.56 (-3.59%) - 03/02/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/27/21
- Wall Street in Fives - Must Read Lists for Monday
- 12/27/21
- Wall Street in Fives - Must Read Lists at Midday
OPA Magnum Opus Acquisition - 03/06/22
- Week in SPAC News: Graf IV said in talks with Urgently
- 02/13/22
- Week in SPAC News: Quantum computing company D-Wave to merge with DPCM Capital
- 02/11/22
- Crypto Currents: Binance takes $200M stake in Forbes
- 05/31/22
- What You Missed On Wall Street On Tuesday
- 05/31/22
- What You Missed On Wall Street This Morning
- 05/23/22
- What You Missed This Week in EVs and Clean Energy
- 05/16/22
- What You Missed This Week in EVs and Clean Energy
- 05/23/22
- Fly Intel: After-Hours Movers
- 04/27/22
- Fly Intel: After-Hours Movers
- 05/27/22
- What You Missed On Wall Street This Morning
- 05/27/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 05/26/22
- What You Missed On Wall Street On Thursday
- 04/13/22
- What You Missed On Wall Street On Wednesday
- 04/13/22
- What You Missed On Wall Street This Morning
- 04/13/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 02/03/22
- Wall Street in Fives - Must Read Lists for Thursday
- 05/23/22
- What You Missed On Wall Street On Monday
- 05/23/22
- What You Missed On Wall Street This Morning
- 05/23/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 05/10/22
- What You Missed On Wall Street On Tuesday
- 05/10/22
- What You Missed On Wall Street This Morning
- 05/10/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- $193.20 /
-0.355 (-0.18%) - 05/25/22
- #SocialStocks: Jack Dorsey steps down from Twitter board, makes room for Musk
- 05/24/22
- What You Missed On Wall Street On Tuesday
- 05/24/22
- What You Missed On Wall Street This Morning
- 04/21/22
- What You Missed On Wall Street On Thursday
- 04/21/22
- What You Missed On Wall Street This Morning
- 04/20/22
- Fly Intel: After-Hours Movers
- $176.91 /
+16.31 (+10.16%) - 06/01/22
- Fly Intel: Pre-market Movers
- 05/31/22
- Fly Intel: After-Hours Movers
- 05/18/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 03/02/22
- What You Missed On Wall Street This Morning
- 03/15/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 03/07/22
- What You Missed On Wall Street On Monday
- 03/07/22
- What You Missed On Wall Street This Morning
- 05/06/22
- Here's What You Missed in Crypto This Week
- 03/28/22
- What You Missed On Wall Street This Morning
- 03/18/22
- Here's What You Missed in Crypto This Week
- 02/14/22
- What You Missed On Wall Street This Morning
- 01/11/22
- Wall Street in Fives - Must Read Lists for Tuesday
- 01/11/22
- Wall Street in Fives - Must Read Lists at Midday
- 04/26/22
- What Wall Street is saying about Alphabet ahead of earnings
- 02/16/22
- What You Missed On Wall Street On Wednesday
- 03/01/22
- What You Missed On Wall Street On Tuesday
- 03/01/22
- What You Missed On Wall Street This Morning
- 05/13/22
- What You Missed On Wall Street On Friday
- 05/13/22
- What You Missed On Wall Street This Morning
- 05/13/22
- Fly Intel: Pre-market Movers
- 05/12/22
- Fly Intel: After-Hours Movers
- 05/26/22
- What You Missed On Wall Street This Morning
- 05/26/22
- Fly Intel: Pre-market Movers
- 05/25/22
- What You Missed On Wall Street On Wednesday
- 05/31/22
- Victoria's Secret options imply 12.5% move in share price post-earnings
VRTX Vertex Pharmaceuticals - 01/10/22
- Early notable gainers among liquid option names on January 10th
- 05/18/22
- Notable open interest changes for May 18th
- 05/17/22
- Notable open interest changes for May 17th
- 05/16/22
- Notable open interest changes for May 16th
- $737.88 /
-20.13 (-2.66%) - 05/23/22
- Notable open interest changes for May 23rd
- 05/19/22
- Notable open interest changes for May 19th
- 03/23/22
- Tempur Sealy put volume heavy and directionally bearish
- 02/28/22
- Tempur Sealy call volume above normal and directionally bullish
- 05/05/22
- Square options imply 10.3% move in share price post-earnings
- 03/23/22
- Square put volume heavy and directionally bearish
- 03/07/22
- Square put volume heavy and directionally bearish
- 02/22/22
- Square put buyer realizes 12% same-day gains
- $337.39 /
-12.56 (-3.59%) - 03/02/22
- Unusually active option classes on open March 2nd
- 05/11/22
- Unusually active option classes on open May 11th
- 06/01/22
- NIO call volume above normal and directionally bullish
- 06/01/22
- Unusually active option classes on open June 1st
- 05/20/22
- Unusually active option classes on open May 20th
- 05/09/22
- Notable open interest changes for May 9th
- 01/31/22
- Two new option listings and three option delistings on January 31st
- 12/30/21
- Largest borrow rate increases among liquid names
- 04/27/22
- Medtronic put volume heavy and directionally bearish
- 01/31/22
- Medtronic put volume heavy and directionally bearish
- 12/16/21
- Medtronic put volume heavy and directionally bearish
- 03/15/22
- LexinFintech options imply 15.0% move in share price post-earnings
- 02/03/22
- Early notable gainers among liquid option names on February 3rd
- 01/12/22
- Unusually active option classes on open January 12th
- 05/31/22
- HP Inc. options imply 7.2% move in share price post-earnings
- 05/27/22
- Early notable gainers among liquid option names on May 27th
- 05/24/22
- HP Inc. put volume heavy and directionally bearish
- 04/29/22
- HP Inc. put volume heavy and directionally bearish
- 05/09/22
- GoodRx Holdings options imply 17.9% move in share price post-earnings
- $193.20 /
-0.355 (-0.18%) - 05/05/22
- Facebook call buyer realizes 131% same-day gains
- 05/02/22
- Early notable gainers among liquid option names on May 2nd
- 04/29/22
- Notable open interest changes for April 29th
- 05/31/22
- Delta Air Lines put volume heavy and directionally bearish
- 05/27/22
- Unusually active option classes on open May 27th
- 05/24/22
- Unusually active option classes on open May 24th
- 04/26/22
- Delta Air Lines put volume heavy and directionally bearish
- $176.91 /
+16.31 (+10.16%) - 06/01/22
- Early notable gainers among liquid option names on June 1st
- 05/31/22
- Salesforce options imply 7.6% move in share price post-earnings
- 05/31/22
- Unusually active option classes on open May 31st
- 02/23/22
- Salesforce call volume above normal and directionally bullish
- 04/27/22
- Capri Holdings put volume heavy and directionally bearish
- 04/07/22
- Capri Holdings call volume above normal and directionally bullish
- 03/04/22
- Capri Holdings put volume heavy and directionally bearish
- 03/03/22
- Capri Holdings put volume heavy and directionally bearish
- 05/23/22
- Largest borrow rate increases among liquid names
- 04/25/22
- Unusually active option classes on open April 25th
- 04/12/22
- Largest borrow rate increases among liquid names
- 12/23/21
- Bitfarms call volume above normal and directionally bullish
- 02/10/22
- Original BARK Company options imply 11.5% move in share price post-earnings
- 05/31/22
- Digital Turbine options imply 14.6% move in share price post-earnings
- 05/16/22
- Digital Turbine call volume above normal and directionally bullish
- 05/10/22
- Digital Turbine call volume above normal and directionally bullish
- 04/25/22
- Digital Turbine call volume above normal and directionally bullish
- 05/31/22
- Ambarella options imply 14.2% move in share price post-earnings
- 05/13/22
- Notable open interest changes for May 13th
- 05/12/22
- Affirm Holdings options imply 29.7% move in share price post-earnings
- 04/25/22
- Affirm Holdings call volume above normal and directionally bullish
- 04/22/22
- Affirm Holdings call volume above normal and directionally bullish
- 06/01/22
- Notable open interest changes for June 1st
- 05/31/22
- Notable open interest changes for May 31st
- 05/27/22
- Notable open interest changes for May 27th
- 05/24/22
- Notable open interest changes for May 24th
|